【摘要】 目的评价重组人血管内皮抑制素注射液(恩度)联合卡培他滨治疗晚期乳腺癌的有效性和安全性。方法经病理学确定的Ⅳ期乳腺癌患者6例,其中浸润性导管癌4例,浸润性小叶癌1例,髓样癌1例,均接受恩度联合卡培他滨的治疗。恩度15 mg加生理盐水500 ml匀速缓慢静脉滴注1~14 d,间歇7 d,重复给药;卡培他滨每日2 500 mg/m2分早、晚2次口服,于饭后半小时用水吞服,1~14 d,休息7 d,21 d为一周期。按照RECIST标准评价近期疗效,参照Kamofsky评分(KPS)变化评价生活质量(QOL)。按照NCI.CTC3.0版标准评价毒性反应,用药1周期即可评价毒性,2周期后方可评价疗效。结果6例患者均可评价客观疗效和安全性。共完成26个周期,平均为4.3个周期,获得CR 1例、PR 2例、SD 2例、PD 1例。客观有效率(RR)(3/6),疾病控制率(DCR)(5/6),生活质量改善者4例、稳定1例、下降1例。C3/4级毒性主要与化疗药物有关,白细胞下降1例,血小板下降1例,恶心、呕吐1例。结论恩度联合卡培他滨治疗晚期乳腺癌具有协同作用,疗效好,毒性低,安全性好,可改善患者的生活质量,值得进一步研究观察。更多还原

【Abstract】 Objective To evaluate the validity and drug safety of Edostar and capecitabine on terminal breast canner.Methods Six stage Ⅳ breast cancer patients by pathological were observed.4 cases of breast infiltrative ductal carcinoma,one case of breast invasive lobular carcinom and one case of breast medullary carcinoma were treated with Edostar and Capecitabine.Capecitabine(2500 mg/m~2,twice per day) was performed with orally administration in the first 14 days in one course of treatment(21 days).Edostar(15 mg in 500 ml saline) was injected intravenously in the first 14 days too.Then evaluated the effection by RECIST,the live quality by KPS and adverse reaction by NCL.CTC3.0.The adverse reaction was evaluated after two courses of treatment.Results 26 cycles of treatment was performed to the six patients.CR,PR,SD and PD took place in one case,two cases,two cases and one case respectively.The RR was(3/6) and the DCR was(5/6).Having good quality life,stable life and bad quality life was four cases,one case and one case respectivaly. The stage G 3/4 adverse reaction was correlate to Edostar and cappcitabine.The decreasing levels of interleukin,platelet were took place in two patients respectively.And nausea and vomit was took place in one patients.Conclusions The Edostar and Capecitabine on terminal breast cancer has advantages including good therapeutic effects,less adverse reaction and high quality live for the patients and it worth further study.更多还原